Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

MONTREUX EQUITY PARTNERS IV LP

2. Date of Event Requiring Statement (MM/DD/YYYY) 7/15/2014

3. Issuer Name and Ticker or Trading Symbol

EPIRUS Biopharmaceuticals, Inc. [EPRS]

(Last) (First) (Middle)

ONE FERRY BUILDING, SUITE 255

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director ___ X ___ 10% Owner
_____ Officer (give title below) _____ Other (specify below)

(Street)

SAN FRANCISCO, CA 94111

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	19524459	D ⁽¹⁾
Common Stock	2714764	D ⁽²⁾

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:
( 1)	John J. Savarese, M.D., Howard D. Palefsky, and Daniel K. Turner III are the managers of Montreux Equity Management IV, LLC, which is the sole general partner of Montreux Equity Partners IV, L.P., which directly holds 19,524,459 shares of Common Stock ("Common Stock") of EPIRUS Biopharmaceuticals, Inc. (the "Issuer"). By reason of these relationships, Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.
( 2)	Daniel K. Turner III is the sole manager of Montreux Equity Management V, LLC, which is the sole general partner of Montreux Equity Partners V, L.P., which directly holds 2,714,764 shares of Common Stock of the Issuer. By reason of these relationships, Montreux Equity Management V, LLC and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management V, LLC and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
MONTREUX EQUITY PARTNERS IV LP ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO, CA 94111		X
Montreux Equity Partners V, L.P. ONE FERRY BUILDING, SUITE 255 SAN FRANCISCO, CA 94111		X

Signatures
/s/ Daniel K. Turner III, Manager, for Montreux Equity Management IV, LLC as general partner of Montreux Equity Partners IV, L.P.		7/25/2014
^** Signature of Reporting Person		Date
/s/ Daniel K. Turner III, Manager, for Montreux Equity Management V, LLC as general partner of Montreux Equity Partners V, L.P.		7/25/2014
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.